Hikma Pharmaceuticals PLC
LSE:HIK
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722.5
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Free Cash Flow
Hikma Pharmaceuticals PLC
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Free Cash Flow
$379m
|
CAGR 3-Years
28%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Free Cash Flow
£5.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Free Cash Flow
$7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
55%
|
CAGR 10-Years
6%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Free Cash Flow
-$103.8m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Free Cash Flow
-$279m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Free Cash Flow
£33.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
|
Hikma Pharmaceuticals PLC
Glance View
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
See Also
What is Hikma Pharmaceuticals PLC's Free Cash Flow?
Free Cash Flow
379m
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Free Cash Flow amounts to 379m USD.
What is Hikma Pharmaceuticals PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
2%
Over the last year, the Free Cash Flow growth was 2%. The average annual Free Cash Flow growth rates for Hikma Pharmaceuticals PLC have been 28% over the past three years , 6% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
